Abstract:<span class="a-plus-plus abstract-section id-a-sec1 outputmedium-all"><p class="a-plus-plus">Coronavirus disease 2019 (COVID-19) is a pandemic viral disease caused by SARS-CoV-2 that generated serious damages for both the human population and the global economy. Therefore, it is currently considered as one of the most important global health problems of human societies and there is an urgent need for potent drugs or vaccines which can effectively combat this virus. The chymotrypsin-like protease (3CLpro) of SARS-CoV-2 plays a key role in the viral replication inside the host and thus is a promising drug target to design and develop effective antiviral drugs against SARS and other coronaviruses. This study evaluated some antiviral coumarin phytochemicals as potential inhibitors of coronaviruses 3CLpro by in silico approaches such as molecular docking, ADMET prediction, molecular dynamics simulation, and MM-PBSA binding energy calculation. Natural coumarin derivatives were docked to the 3CLpro of SARS-CoV-2 and for further investigation, docked to the 3CLpro of SARS-CoV and MERS-CoV. The docking scores of these natural compounds were compared with 3CLpro referenced inhibitors (ritonavir and lopinavir) and co-crystal inhibitor N3. Molecular docking studies suggested more than half of the coumarin phytochemicals had favorable interaction at the binding pocket of the coronaviruses 3CLpro and exhibited better binding affinities toward 3CLpro than ritonavir and lopinavir. Most antiviral phytochemicals interact strongly with one or both the catalytic dyad residues (His41 and Cys145) and the other key residues of SARS-CoV-2 main protease. Further, MD simulation and binding free energy calculations using MM-PBSA were carried out for three 3CLpro-coumarin complexes and 3CLpro-N3/lopinavir. The results confirmed that the 3CLpro-glycycoumarin, 3CLpro-oxypeucedanin hydrate, and 3CLpro-inophyllum P complexes were highly stable, experience fewer conformation fluctuations and share a similar degree of compactness. Also, the pharmacokinetics and drug-likeness studies showed good results for the selected coumarin phytochemicals.Therefore, the coumarin phytochemicals could be used as antiviral agents in the treatment of COVID-19 after further studies.</p></span>

Pharmacological perspectives and molecular mechanisms of coumarin derivatives against virus disease

Coumarin: An emerging antiviral agent

Coumarin-based derivatives with potential anti-HIV activity

Advances in Pharmacology and Toxicology of Coumarins

Current Developments of Coumarin Compounds in Medicinal Chemistry

Recent progress in the antiviral activity and mechanism study of pentacyclic triterpenoids and their derivatives

Heterocyclic compounds as antiviral drugs: Synthesis, structure–activity relationship and traditional applications

Coumarin‐containing hybrids and their antibacterial activities

Coumarins as Potential Antiprotozoal Agents: Biological Activities and Mechanism of Action

Medicinal plants: Treasure for antiviral drug discovery

HBV Covalently Closed Circular DNA Targeting by Plant-Derived Chemical Agent: Exploring the Potential of Coumarins

Design, Synthesis, and Biological Activities of Novel Coumarin Derivatives as Pesticide Candidates

Molecular Insights into Coumarin Analogues as Antimicrobial Agents: Recent Developments in Drug Discovery

Antiviral activity of bioactive phytocompounds against coronavirus: An update

In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2

Natural product coumarins: biological and pharmacological perspectives

Medicinal chemistry strategies toward broad-spectrum antiviral agents to prevent next pandemics

Recent Research Progress: Discovery of Anti-Plant Virus Agents Based on Natural Scaffold

Recent advances in antiviral activities and potential mechanisms of sulfated polysaccharides

[Research progress in biosynthesis-related enzymes of coumarin compounds and their bioactivities]

A Mini-Review on the Common Antiviral Drug Targets of Coronavirus